Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent analysis of data in the FDA Adverse Event Reporting System by Fadini and colleagues adds to this concern.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Cardiovascular Diabetology Open Access 29 March 2019
-
Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
Diabetology & Metabolic Syndrome Open Access 01 December 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tahrani, A. A., Barnett, A. H. & Bailey, C. J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 1, 140–151 (2013).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Rodbard, H. W. et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 40, 171–180 (2017).
Umpierrez, G. & Korytkowski, M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat. Rev. Endocrinol. 12, 222–232 (2016).
U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. FDA http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf (2015).
European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined. EMA http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf (2015).
Hayami, T. et al. Case of ketoacidosis by a sodium–glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J. Diabetes Investig. 6, 587–590 (2015).
Erondu, N., Desai, M., Ways, K. & Meininger, G. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 38, 1680–1686 (2015).
Henry, R. R., Thakkar, P., Tong, C., Polidori, D. & Alba, M. Efficacy and safety of Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38, 2258–2265 (2015).
Fadini, G. P., Bonora, B. M. & Avogaro, A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia http://dx.doi.org/10.1007/s00125-017-4301-8 (2017).
Acknowledgements
G.E.U. is partly supported by research grants from the Public Health Service (Grant UL1 RR025008 from the Clinical and Translational Science Award program), and the US National Institutes of Health and National Center for Research Resources (1P30DK111024-01).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.E.U. has received unrestricted research support for investigator-initiated studies (paid to Emory University) from AstraZeneca, Boehringer Ingelheim, Merck, Novo Nordisk and Sanofi.
Rights and permissions
About this article
Cite this article
Umpierrez, G. SGLT2 inhibitors and diabetic ketoacidosis — a growing concern. Nat Rev Endocrinol 13, 441–442 (2017). https://doi.org/10.1038/nrendo.2017.77
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.77
This article is cited by
-
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Cardiovascular Diabetology (2019)
-
Management of Diabetes in Patients Undergoing Bariatric Surgery
Current Diabetes Reports (2019)
-
Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
Diabetology & Metabolic Syndrome (2017)
-
Orale Triple-Therapie – sinnvolle Strategie oder nur Verzögerungstaktik?
Der Diabetologe (2017)